Eculizumab biosimilar (Amgen)

依库珠单抗生物类似药（安进）

Report date: 2024/05/29 16:32:14

Base Information

Drug NameEculizumab biosimilar (Amgen)
Drug Alias Name依库丽单抗生物仿制药（安进）Eculizumab-AEEB依库丽单抗生物类似药（安进）BKEMVABP-959
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Global Approved IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/05/28
Country/TerritoryCzechiaUnited StatesSweden +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeL04AJ01
Related LinksN/A